Targeting the PD-1/PD-L1 checkpoint has occupied a stable space in the treatment of advanced NSCLC and this is still changing; the combination of nivolumab and ipilimumab demonstrated overall survival benefit in the first-line setting, regardless of PD-L1 status and Tumour Mutational Burden (Checkmate-227) [49]. Here, CD274 is linked to non-small cell lung carcinoma.